Neurotech International reported positive Phase 2/3 results for NTI164 in autism spectrum disorder patients.

The study showed a 36% improvement from weeks 8 to 12 and a 56% enhancement from baseline over 12 weeks.

Patients initially on placebo demonstrated a 21% improvement after four weeks on NTI164.

The trial involved 54 ASD patients in a randomised, double-blind format, and no serious adverse events were reported from weeks 9 to 12.